Building ‘Smart’ Cell-Based Therapies
A Northwestern synthetic biology team has created a new technology for modifying human cells to create programmable therapeutics that could travel the body and selectively target cancer and other sites of disease.
Engineering cell-based, biological devices that monitor and modify human physiology is a promising frontier in clinical synthetic biology. However, no existing technology enabled bioengineers to build such devices that sense a patient’s physiological state and respond in a customized fashion.
“The project addressed a key gap in the synthetic biology toolbox,” says Joshua Leonard, assistant professor of chemical and biological engineering in Northwestern’s McCormick School of Engineering and Applied Science. “There was no way to engineer cells in a manner that allowed them to sense key pieces of information about their environment, which could indicate whether the engineered cell is in healthy tissue or sitting next to a tumor.”
Funded by the National Academies Keck Futures Initiative and the Defense Advanced Research Projects Agency, the research is available to read online in the journal ACS Synthetic Biology.
Leonard’s team worked for nearly four years to close this gap. The end result is a protein biosensor that sits on the surface of a cell and can be programmed to sense specific external factors. For example, the engineered cell could detect big, soluble protein molecules that indicate that it’s next to a tumor. When the biosensor detects such a factor, it sends a signal into the engineered cell’s nucleus to activate a gene expression program, such as the production of tumor-killing proteins or chemicals. Since this toxic program would be activated only near tumor cells, such an approach could minimize side effects as well as improve therapeutic benefits.
Called a Modular Extracellular Sensor Architecture (MESA), the biosensor platform is completely self-contained so that several different biosensors can be present in a single cell without interfering with one another, allowing bioengineers to build increasingly sophisticated functional programs. The platform is also highly modular, enabling the biosensors to be customized to recognize factors of relevance to various patients’ needs.
“By linking the output of these biosensors to genetic programs, one can build in a certain logical command, such as ‘turn the output gene on when you sense this factor but not that factor,’” Leonard explains. “In that way, you could program a cell-based therapy to specify which cells it should kill.”
Leonard says doctors could potentially collect immune cells from a patient’s body, engineer the cells using MESA, and put them back into the patient. From there, the cells would do the work of detecting cancer or the disease they are designed to identify.
The Latest on: Smart Cell-Based Therapies
via Google News
The Latest on: Smart Cell-Based Therapies
- UPDATE 1-Vertex to buy cell therapy developer Semma for $950 mlnon September 3, 2019 at 5:42 am
Semma focuses on developing cell-based therapies that have been shown to control blood glucose ... (Alliance News) - Frontier Smart Technologies Group Ltd said Tuesday it has amended the loan agreed ...
- Vertex to Acquire Semma Therapeutics With a Goal of Developing Curative Cell-Based Treatments for Type 1 Diabeteson September 3, 2019 at 5:00 am
This breakthrough technology has been exclusively licensed to Semma for the development of a cell-based therapy for diabetes ... SK Telecom unveils ‘5G Smart Office’ .. Formula E Korea E-Prix 2020 ...
- Qrons to Present at the RHK Capital 4th Annual Disruptive Growth Conference Hosted by ReedSmithon August 26, 2019 at 5:30 am
About Qrons Inc. Headquartered in New York City, Qrons is a publicly traded emerging biotechnology company developing advanced cell-based solutions to combat neuronal ... modified mesenchymal stem ...
- Stem cells could regenerate organs – but only if the body won’t reject themon August 19, 2019 at 8:11 am
This renders them susceptible to rejection when used as part of stem cell-based treatment. We showed in ... to transform health care. [ You’re smart and curious about the world.
- Smart Cells release 21st Stem Cell Sample to treat a child with Cerebral Palsyon July 29, 2019 at 5:00 pm
Dr Ann Smith, Scientific Director Scientific Director, at Smart Cells: "Treatment centres must ensure the safety and efficacy of stem cell based therapies for human application. At SC, we work to high ...
- First Utahns treated in nationwide FDA-allowed clinical study of locally developed cell therapy for chronic low back painon July 10, 2019 at 1:00 am
The SMART Clinic's President and Co-founder ... DiscGenics is a privately held, clinical stage biotechnology company focused on developing regenerative cell-based therapies that alleviate pain and ...
- First Utahns treated in nationwide FDA-allowed clinical study of locally developed cell therapy for chronic low back painon July 9, 2019 at 5:00 pm
"The SMART Clinic is committed to changing the way spine conditions ... DiscGenics is a privately held, clinical stage biotechnology company focused on developing regenerative cell-based therapies ...
- Horizon Discovery’s SMARTvector shRNA Technology Deployed in Celyad’s Successful IND Filing for Next-Generation CAR-T Cell Therapy, CYAD-02on July 8, 2019 at 12:36 am
CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell-based therapies, received FDA Acceptance of Investigational New Drug (IND) application for the autologous ...
- Enabling technology in cell-based therapies: Scale-up, scale-out or program in-placeon July 22, 2018 at 11:13 pm
Advances reported in this issue include methods of cell separation that utilize unique microscale forces for use with higher cell concentrations or larger sample volumes; techniques, device packages ...
via Bing News